UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 20, 2013

 

 

IDENIX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-49839   45-0478605

(State or other jurisdiction

of incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

60 Hampshire Street

Cambridge, MA

  02139
(Address of principal executive offices)   (Zip Code)

(617) 995-9800

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers

(e) At a meeting of the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Idenix Pharmaceuticals, Inc. (the “Company”) held on February 20, 2013, the Committee authorized the payment of annual bonus and equity awards to the Company’s executive officers (other than Ronald C. Renaud, Jr., the Company’s President and Chief Executive Officer) identified below for services rendered during the year ended December 31, 2012.

Additionally, the Committee approved annual base salaries and targets for cash bonus and equity incentives for 2013 for each of these executive officers. The Committee proposed a recommendation to the Company’s Board regarding Mr. Renaud’s annual bonus and equity awards for services rendered during 2012 and his base salary and targets for cash bonus and equity incentives for 2013.

At a subsequent meeting of the Board held on February 21, 2013, the Board authorized the payment of an annual bonus award and the grant of the equity award to Mr. Renaud for services rendered during the year ended December 31, 2012 and approved his annual base salary and targets for cash bonus and equity incentives for 2013 based upon the Committee’s recommendation.

The Committee and the Board’s respective determinations were made following a comprehensive review of market data provided by an independent compensation consultant and the level of achievement of both corporate and individual performance goals for the year ended December 31, 2012.

Identified below is the 2012 cash bonus award and 2013 annual base salary, target cash bonus and equity incentive data with respect to each of the Company’s “named executive officers” (as used in Instruction 4 to Item 5.02 of Form 8-K). For each named executive officer, the 2012 cash bonus was based on the Company’s performance of corporate goals related to preclinical, clinical, regulatory, financial and strategic targets. In addition to these corporate goals, which were applicable to all of the Company’s executive officers, individual performance goals specific to executive officers were also considered.

Each executive officer named below is a party to a written employment arrangement with the Company. These agreements and arrangements have been filed as exhibits to the Company’s annual and quarterly reports on file with the Securities and Exchange Commission. These arrangements provide for the annual payment of bonuses in a range from zero to 200% of the target bonus amount, dependent upon achievement of the previously determined performance goals. The bonus targets for each officer were established in the respective employment arrangements. To the extent that such bonus targets increase, the newly increased bonus target amount becomes the minimum bonus target amount for all future periods remaining during the term of the employment arrangement. The Committee may, in its discretion, review the target bonus and target option award for the executive officers named below at any time during the calendar year.

 

     2012     2013  

Named Executive Officer

   Cash
Bonus
     Option
Grant
(shares)(1)
    Base
Salary
     Target
Bonus
(% of base
salary)
    Target
Option
Award
(shares)
 

Ronald C. Renaud, Jr.

   $ 232,000         500,000 (2)    $ 550,000         60     350,000   

President and Chief Executive Officer

            

Daniella Beckman(3)

     75,000         100,000 (2)      335,000         50     85,000   

Senior Vice President, Chief Financial Officer and Treasurer

            

Douglas Mayers

     110,000         120,000 (2)      380,000         50     120,000   

Executive Vice President and Chief Medical Officer

            

David Standring

     93,000         95,000 (2)      340,000         50     120,000   

Executive Vice President and Chief Scientific Officer

            

Maria Stahl

     92,500         100,000 (2)      340,000         50     100,000   

Senior Vice President, General Counsel

            


(1) The options have been granted pursuant to our stock incentive plans and are evidenced by stock option agreements that been approved by the Committee. The terms and conditions of these awards are substantially consistent with those granted to other employees of the Company. These terms and conditions are set forth in the employment agreements or arrangements between the Company and the respective officer.
(2) The option vests in 48 equal monthly installments beginning on February 28, 2013.
(3) Ms. Beckman was promoted to Vice President Chief Financial Officer and Treasurer in June 2011. She was promoted to Senior Vice President, Chief Financial Officer and Treasurer on February 29, 2012.

Additional information regarding compensation of executive officers will be included in the Company’s proxy statement to be filed in connection with its 2013 Annual Meeting of Stockholders to be held on June 6, 2013.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.

 

    IDENIX PHARMACEUTICALS, INC.

Date: February 26, 2013

    By:  

/s/ Maria Stahl

      Maria Stahl
      Senior Vice President and General Counsel